Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series
- 17 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 67 (1), 252-258
- https://doi.org/10.1007/s10620-021-06884-9
Abstract
Background Inflammatory bowel diseases (IBD) are often treated with anti-tumor necrosis factor alpha (anti-TNFα) medications. Concomitant treatment of IBD with anti-TNFα agents and immunomodulators appears to be associated with an increased risk for lymphoma. Methods Patients who developed lymphoma while on monotherapy with an anti-TNFα agent were identified at three centers. Institutional Review Board approval was obtained. Results Five adolescents and young adult patients with pediatric-onset IBD who were treated with infliximab (IFX) without exposure to thiopurines were subsequently diagnosed with lymphoma. Three of the five patients had bone involvement at presentation. Epstein–Barr virus was positive in 2 cases. Median time from diagnosis of IBD and exposure to IFX prior to diagnosis of lymphoma was 5 and 4.3 years, respectively. Conclusions This case series reports long-term follow-up for young patients with IBD who were treated with IFX monotherapy and developed lymphoma. Three of the five patients had bone involvement. In general, the risk of lymphoma following exposure to anti-TNFα medications alone remains low, but the incidence of primary bone lymphomas in IBD has not been reported. Studies examining longer exposure times may be needed to determine the true lymphoma risk in patients treated with IFX monotherapy.Keywords
This publication has 25 references indexed in Scilit:
- Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐α therapy in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2014
- Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort StudyGastroenterology, 2013
- T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH StudyThe American Journal of Gastroenterology, 2013
- Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studiesClinical Rheumatology, 2011
- Malignant hematologic diseases in adolescents and young adultsBlood, 2011
- Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registryAnnals Of The Rheumatic Diseases, 2009
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Risk of haematopoietic cancer in patients with inflammatory bowel diseaseGut, 2005
- Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm CountyGut, 2004